Feasibility Study of R-CHOP Plus Bevacizumab in Patients With Diffuse Large B Cell Lymphoma (DLBCL).

Trial Profile

Feasibility Study of R-CHOP Plus Bevacizumab in Patients With Diffuse Large B Cell Lymphoma (DLBCL).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide; Doxorubicin; Methotrexate; Prednisolone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jul 2017 Status changed from active, no longer recruiting to discontinued.
    • 31 May 2012 Status changed from discontinued to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 31 May 2012 United Kingdom Clinical Research Network reports accrual to date changed from 14% to 28%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top